Can a U.S.-Proven strategy boost survival for chinese kids with rare hodgkin lymphoma?
NCT ID NCT04726501
First seen Mar 21, 2026 · Last updated Apr 29, 2026 · Updated 8 times
Summary
This study tests whether a treatment plan that works well in the U.S. can also help Chinese children and teens with newly diagnosed Hodgkin lymphoma. About 200 participants aged 1 to 18 will receive the modified therapy, and researchers will track how long they stay cancer-free and overall survival. The goal is to identify challenges in current care and improve future treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Nanjing Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Nanjing, China
-
Shanghai Children's Medical Center
Shanghai, 200127, China
-
West China Second University Hospital, Sichuan University, Chengdu, China
Chengdu, China
Conditions
Explore the condition pages connected to this study.